ClinicalTrials.gg
TerminatedNCT05543928Updated Jul 25, 2025Results posted

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

A Phase 3 interventional study of CTAP101 and Placebo in Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 and Vitamin d Deficiency, sponsored by OPKO Health, Inc.. Terminated at 2 sites in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by OPKO Health, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
FDA changed the post-marketing requirement necessitating a new study design and protocol.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 250 studies in Vitamin D Deficiency with a site in United States — 10 open to participants now, 18 under way, none of them phase 3. Vitamin D Deficiency · United States.

Enrollment
201st of 214
2 · median 58
Started
2023
with 3 others
Phase 3
17 of 250
none open now
Registered
239th of 250
by date

Among the 250 studies in Vitamin D Deficiency with a site in United States, this one is the 201st largest by enrollment of the 214 interventional ones that give a count, is one of 4 that started in 2023, is one of 17 in phase 3, and was the 239th registered.

Vitamin D Deficiency

800 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

Browse Vitamin D Deficiency studies →

Open to participants now

10 of the 250 studies in Vitamin D Deficiency with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Vitamin D Deficiency studies recruiting now, 16 (43%) set no upper age limit and 18 (49%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 250 studies in Vitamin D Deficiency with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.

03

Conditions studied

  • Chronic Kidney Disease stage3
  • Chronic Kidney Disease stage4
  • Vitamin d Deficiency
  • Secondary Hyperparathyroidism
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cohort 1: Be 12 to \<18 years of age and have a body weight of ≥40 kg; Cohort 2: be 8 to \<12 years of age and have a body weight of ≥20 kg.
  2. Be diagnosed with stage 3 to 4 CKD at least six months prior to the screening visit, and have an of ≥15 to \<60 mL/min/1.73m2 at screening.
  3. Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation, including:

    1. Serum albumin ≤ 3.0 g/dL;
    2. Serum transaminase ( or SGPT, AST or SGOT) > 2.5 times the at screening; and,
    3. Urinary albumin excretion of >3000 mcg/mg creatinine.
  4. Exhibit during the initial or, if necessary, a screening visit after washout:

    1. Plasma iPTH >100 pg/mL (stage 3 CKD) or >160 pg/mL (stage 4 CKD)
    2. Serum calcium \<9.8 mg/dL (corrected for albumin);
    3. Serum total 25-hydroxyvitamin D \<30 ng/mL; and,
    4. Serum phosphorus >2.5 to ≤5.5 mg/dL (12 to \<18 years) or ≤6.0 mg/dL (ages 8 to \<12 years).
  5. If taking calcitriol or other 1α-hydroxylated vitamin D analogs, or cinacalcet, be willing to forgo treatment with these agents for the duration of the study and complete an 8-week prior to commencing treatment in the study.
  6. If taking >1,000 mg/day of elemental calcium, discontinue or reduce calcium use and/or use non-calcium based therapies for the duration of the study.
  7. If receiving ≤1,700 IU/day nutritional vitamin D (ergocalciferol or cholecalciferol) therapy, must agree to remain on a stable dose during the study.
  8. If taking >1,700 IU/day of nutritional vitamin D, must discontinue or decrease the dose to ≤1,700 IU/day, maintain that dose for the duration of the study, and complete an 8-week washout period prior to commencing treatment in the study provided that serum total 25-hydroxyvitamin D is ≥30 ng/mL. The washout period is not necessary if serum total 25-hydroxyvitamin D is \<30 ng/mL.
  9. If taking any bone modifying treatment that could interfere with study endpoints, must discontinue use of such agent(s) for the duration of the study.
  10. Willing and able to comply with study instructions and commit to all clinic visits for the duration of the study.
  11. Female subjects of must be neither pregnant nor lactating and must have a negative urine pregnancy test at the first screening visit.
  12. All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study.
  13. Each subject or their legal representative must be able to read, understand and sign the form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. History of or planned kidney transplant or parathyroidectomy.
  2. History (prior three months) of serum calcium ≥9.8 mg/dL.
  3. Use of bisphosphonate therapy (denosumab) within six months prior to enrollment.
  4. Known previous or concomitant serious illness or medical condition, such as , , significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis, or physical condition that in the opinion of the investigator may worsen and/or interfere with participation in the study.
  5. History of neurological/psychiatric disorder, including psychotic disorder, or any reason which, in the opinion of the investigator makes adherence to a treatment or follow up schedule unlikely.
  6. Known or suspected to any of the constituents of either product.
  7. Currently participating in, or has participated in, an interventional/investigational study within 30 days prior to study screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2 participants (actual)

Study arms

  • Placebo comparator
    Cohort 1 and Cohort 2 Placebo

    Drug: Placebo

  • Experimental
    Cohort 1 and Cohort 2 CTAP101 Capsule

    Drug: CTAP101

Interventions

  • CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Numbers of Subjects Who Attained Mean Decrease in Plasma iPTH of 30% From Baseline

    The primary efficacy endpoint is the proportion of subjects in the intent-to- treat (ITT) population (age 8 to \<18 years) attaining a mean decrease in plasma iPTH of at least 30% from pre-treatment baseline compared to placebo during the EAP.

    Time frame: 26 weeks

  2. Safety and Tolerability

    Safety and tolerability will be evaluated in the safety population by AEs, PEs, VS, hematology and laboratory evaluations, and ECGs.

    Time frame: 26 weeks

  3. Pharmacokinetic

    To assess the pharmacokinetic (PK) profile of 25-hydroxyvitamin D3 after repeated doses of CTAP101 Capsules in pediatric subjects

    Time frame: 26 weeks

Secondary outcomes

  1. Level of Serum Total 25-hydroxyvitamin D at ≥30 ng/mL Compared to Placebo

    To evaluate the efficacy of repeated dosing with CTAP101 Capsules versus placebo in raising serum total 25-hydroxyvitamin D to ≥30 ng/mL

    Time frame: 26 weeks

  2. Plasma iPTH Mean Absolute Changes and Serum Total 25-hydroxyvitamin D

    To determine the time courses of mean absolute changes from pre-treatment baseline in serum total 25-hydroxyvitamin D and plasma iPTH during administration of repeated doses of CTAP101 Capsules

    Time frame: 26 weeks

  3. Pharmacodynamic Effects of Repeated Doses of CTAP101 Capsules

    To assess the PD effects of repeated doses of CTAP101 Capsules versus placebo on mean serum calcium (corrected for albumin), serum phosphorus and serum calcium-times-phosphorus (CaxP) product, and the change in mean urine calcium:creatinine ratio

    Time frame: 26 weeks

  4. Incidence of Hypercalcemia and Hyperphosphatemia

    To evaluate the safety of CTAP101 Capsules versus placebo with regard to the incidence of hypercalcemia and hyperphosphatemia

    Time frame: 26 weeks

07

Results

Posted Jul 25, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 and Cohort 2 PlaceboCohort 1 and Cohort 2 CTAP101 Capsule
Started00
Completed00
Not completed00

Outcome measures

PrimaryNumbers of Subjects Who Attained Mean Decrease in Plasma iPTH of 30% From Baseline

The primary efficacy endpoint is the proportion of subjects in the intent-to- treat (ITT) population (age 8 to \<18 years) attaining a mean decrease in plasma iPTH of at least 30% from pre-treatment baseline compared to placebo during the EAP.

Time frame:
26 weeks

No measurements were reported for this outcome.

PrimarySafety and Tolerability

Safety and tolerability will be evaluated in the safety population by AEs, PEs, VS, hematology and laboratory evaluations, and ECGs.

Time frame:
26 weeks

No measurements were reported for this outcome.

PrimaryPharmacokinetic

To assess the pharmacokinetic (PK) profile of 25-hydroxyvitamin D3 after repeated doses of CTAP101 Capsules in pediatric subjects

Time frame:
26 weeks

No measurements were reported for this outcome.

SecondaryLevel of Serum Total 25-hydroxyvitamin D at ≥30 ng/mL Compared to Placebo

To evaluate the efficacy of repeated dosing with CTAP101 Capsules versus placebo in raising serum total 25-hydroxyvitamin D to ≥30 ng/mL

Time frame:
26 weeks

No measurements were reported for this outcome.

SecondaryPlasma iPTH Mean Absolute Changes and Serum Total 25-hydroxyvitamin D

To determine the time courses of mean absolute changes from pre-treatment baseline in serum total 25-hydroxyvitamin D and plasma iPTH during administration of repeated doses of CTAP101 Capsules

Time frame:
26 weeks

No measurements were reported for this outcome.

SecondaryPharmacodynamic Effects of Repeated Doses of CTAP101 Capsules

To assess the PD effects of repeated doses of CTAP101 Capsules versus placebo on mean serum calcium (corrected for albumin), serum phosphorus and serum calcium-times-phosphorus (CaxP) product, and the change in mean urine calcium:creatinine ratio

Time frame:
26 weeks

No measurements were reported for this outcome.

SecondaryIncidence of Hypercalcemia and Hyperphosphatemia

To evaluate the safety of CTAP101 Capsules versus placebo with regard to the incidence of hypercalcemia and hyperphosphatemia

Time frame:
26 weeks

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 and Cohort 2 Placebo———
Cohort 1 and Cohort 2 CTAP101 Capsule———

Baseline characteristics

The study was terminated before randomization

Age, Categorical
Age, CategoricalCohort 1 and Cohort 2 PlaceboCohort 1 and Cohort 2 CTAP101 CapsuleTotal
<=18 years———
Between 18 and 65 years———
>=65 years———
Age, Continuous
Age, ContinuousCohort 1 and Cohort 2 PlaceboCohort 1 and Cohort 2 CTAP101 CapsuleTotal
Sex: Female, Male
Sex: Female, MaleCohort 1 and Cohort 2 PlaceboCohort 1 and Cohort 2 CTAP101 CapsuleTotal
Female———
Male———
Race (NIH/OMB)
Race (NIH/OMB)Cohort 1 and Cohort 2 PlaceboCohort 1 and Cohort 2 CTAP101 CapsuleTotal
American Indian or Alaska Native———
Asian———
Native Hawaiian or Other Pacific Islander———
Black or African American———
White———
More than one race———
Unknown or Not Reported———
Region of Enrollment
Region of Enrollment(participants)Cohort 1 and Cohort 2 PlaceboCohort 1 and Cohort 2 CTAP101 CapsuleTotal
08

Study locations

2 sites
  • OPKO Study Site
    Columbus, Ohio 43205, United States
  • OPKO Study Site
    Greenville, South Carolina 29615, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Jun 2024, 16 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2022
First posted
Sep 16, 2022
StartActual
Jan 31, 2023
Primary completionActual
Jun 19, 2024
CompletionActual
Jun 19, 2024
Results first posted
Jul 25, 2025
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05543928
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Jan 31, 2023
Primary completion
Jun 19, 2024
Completion
Jun 19, 2024
Results posted
Jul 25, 2025
Last update
Jul 25, 2025

Study contacts

Akhtar Ashfaq, MD
study director · OPKO Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Modified-release Calcifediol Capsule

Start the discussion